> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Vir's Prostate Cancer Drug VIR-5500 Gets FDA Fast Track Status, With Phase 3 Planned For 2027
- URL: https://www.bullished.co/virs-prostate-cancer-drug-vir-5500-gets-fda-fast-track-status-with-phase-3-planned-for-2184e666/
- Published: 2026-10-08T12:51:01.000Z
- Updated: 2026-10-08T12:51:01.000Z
- Description: The designation covers late-line metastatic castration-resistant prostate cancer; Vir and Astellas co-develop the drug.
- Author: Matteo Parrino
- Tags: SEC Filings, VIR, Industry: Healthcare

The FDA has granted [Fast Track designation](https://www.sec.gov/Archives/edgar/data/0001706431/000162828026065408/vir-20261008.htm?ref=bullished.co) to Vir Biotechnology's VIR-5500 for late-line metastatic castration-resistant prostate cancer, according to an 8-K the company filed Thursday. The company says it expects to begin Phase 3 trials in 2027.

## What the 8-K says

The filing carries a press release as an [exhibit](https://www.sec.gov/Archives/edgar/data/0001706431/000162828026065408/a2026-10x01%5F8xkxvirx5500fa.htm?ref=bullished.co). It describes VIR-5500 as a PSMA-targeted, dual-masked T-cell engager, a drug built to steer the immune system's T-cells against cancer cells. Astellas Pharma and Vir are co-developing it under a global strategic collaboration.

The release defines Fast Track as a designation meant to facilitate and speed the development and review of drugs for serious conditions that fill an unmet need. It cites a 5-year survival rate of approximately 30% for patients with metastatic castration-resistant prostate cancer.

Vir CEO Marianne De Backer said the designation reflects the drug's potential in an area of "serious unmet need" as the companies "prepare to enter pivotal Phase 3 development in 2027." Moitreyee Chatterjee-Kishore, Executive Vice President and Head of Oncology Development at Astellas, said the designation "reinforces the importance of advancing VIR-5500 with urgency."

## Where the drug stands

VIR-5500 is in a Phase 1 study with six dose-expansion cohorts. Three test it alone, in patients whose disease is taxane naïve, radioligand therapy naïve or radioligand therapy exposed.

Three test combinations: with enzalutamide in early-line mCRPC, with docetaxel in early-line mCRPC, and with darolutamide in metastatic hormone sensitive prostate cancer.

Phase 1 data reported earlier this year showed the drug was generally well tolerated, with promising anti-tumor activity in mCRPC patients. The release warns that early-stage results may not match later-stage trials and do not ensure approval.

The company's stock closed at $11.52 at Wednesday's close, before the filing.

## What to watch

Vir and Astellas anticipate starting pivotal Phase 3 trials in 2027\. Enrollment in the Phase 1 expansion cohorts is ongoing.

The 8-K gives no Phase 3 start date beyond 2027, and the release's own risk language lists enrollment rates, regulatory timing and safety data as factors that could change the plan.

### Sources

- [8-K Filing — Vir Biotechnology, Inc. (VIR)](https://www.sec.gov/Archives/edgar/data/0001706431/000162828026065408/vir-20261008.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit a2026-10x01\_8xkxvirx5500fa.htm — Vir Biotechnology, Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001706431/000162828026065408/a2026-10x01%5F8xkxvirx5500fa.htm?ref=bullished.co) — SEC EDGAR